Agenus restructuring news

In March, Agenus said it will reduce headcount by about 50. The company, which had 255 employees at Feb. 28, did not respond to inquiries.

Agenus said it will focus on the development of its immuno-oncology portfolio of checkpoint inhibitor antibodies, which target PD-1 and cytotoxic T-lymphocyte associated protein 4 (CTLA4; CD152), and its AutoSynVax vaccine. Agenus will close its Basel, Switzerland, site and consolidate operations to Cambridge, U.K., and Lexington, Mass. The company will also focus on its manufacturing operations in Berkeley, Calif...